Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma-Reference-Cited by-同舟云学术

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma

Published:2024-09-05 Issue:11 Volume:73 Page:
ISSN:1432-0851
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Quinn Colin H.,Julson Janet R.,Markert Hooper R.,Nazam Nazia,Butey Swatika,Stewart Jerry E.,Coleman Jennifer C.,Markert James M.,Leavenworth Jianmei W.,Beierle Elizabeth A.

Funder

National Institutes of Health

National Institutes of Health,United States

Kaul Pediatric Research Institute,United States

Rally Foundation for Childhood Cancer Research

Hyundai Hope On Wheels,United States

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00262-024-03818-y.pdf

Reference48 articles.

1. Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33

2. Irwin MS et al (2021) Revised neuroblastoma risk classification system: a report from the children’s oncology group. J Clin Oncol 39(29):3229–3241

3. Yogev O et al (2019) In vivo modeling of chemoresistant neuroblastoma provides new insights into chemorefractory disease and metastasis. Cancer Res 79(20):5382–5393

4. Senzer NN et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27(34):5763–5771

5. Brandetti E et al (2017) MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncoimmunology 6(6):e1316439